Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3552142

N[C@H]1CCN(c2ccc([N+](=O)[O-])cc2)C1.O=C(O)C(F)(F)F

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.49
POLB P06746 2/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
KCNJ1 P48048 1/20 0.48
ALDH1A1 P00352 4/20 0.46
MAPK1 P28482 1/20 0.46
DPP4 P27487 2/20 0.45
DPP8 Q6V1X1 2/20 0.45
DPP9 Q86TI2 2/20 0.45
DPP7 Q9UHL4 2/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NOTUM Q6P988 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3555102 1.00 MAPT (0.49) MAPTPOLBCYP2C9CYP2C19KCNJ1
SCHEMBL2126870 0.88 MAPT (0.56) MAPTPOLBCYP2C9CYP2C19ALDH1A1
SCHEMBL6873751 0.88 MAPT (0.56) MAPTPOLBCYP2C9CYP2C19ALDH1A1
Trifluoroacetic Acid SCHEMBL18214922 0.83 DPP4 (0.60) MAPK1DPP4DPP8DPP9DPP7
Trifluoroacetic Acid SCHEMBL15212493 0.83 DPP4 (0.60) MAPK1DPP4DPP8DPP9DPP7
Trifluoroacetic Acid SCHEMBL3553245 0.82 TOP1 (0.51) MAPTPOLBALDH1A1DPP4DPP8
Trifluoroacetic Acid SCHEMBL5204495 0.82 TOP1 (0.51) MAPTPOLBALDH1A1DPP4DPP8
SCHEMBL31669360 0.81 MAPT (0.49) MAPTPOLBCYP2C9CYP2C19ALDH1A1
SCHEMBL4003076 0.80 MAPT (0.61) MAPTPOLBALDH1A1MAPK1DPP4
SCHEMBL4003069 0.80 MAPT (0.61) MAPTPOLBALDH1A1MAPK1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655652-B2 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis ASTRAZENECA AB (SE) 2010-02-02 US disclosed
US-20070161615-A1 Chemical compounds ASTRAZENECA AB (SE) 2007-07-12 US disclosed
EP-1748999-A1 IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION AstraZeneca AB (SE) 2007-02-07 EP disclosed
WO-2005075461-A1 IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161615-A1 Chemical compounds MKI67, PCNA, CCNI MAPT 3632/4885POLB 315/4885CYP2C9 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.